Janssen-Cilag International NV, of Beerse, Belgium, a Johnson & Johnson subsidiary, said the European Commission approved Zytiga (abiraterone acetate), a once-daily, oral, androgen biosynthesis inhibitor to be used in combination with prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen
BioWorld International | Wednesday, September 14, 2011
Janssen-Cilag International NV, of Beerse, Belgium, a Johnson & Johnson subsidiary, said the European Commission approved Zytiga (abiraterone acetate), a once-daily, oral, androgen biosynthesis inhibitor to be used in combination with prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen
Other animal studies have shown inhibition and regression of tumors, and superiority to irinotecan to treat solid tumors...It also is establishing an in-house team to support Armada, establish other sales channels for Alferon N Injection and educate physicians and patients to drive sales in the U.S., as well as in Asia, Europe and Latin America
The European Commission is putting an additional €12 million (US$17.3million) into antibiotic research following a recent outbreak of Escherichia coli, which infected almost 4,000 people and killed 46
BioWorld International | Wednesday, August 17, 2011
Biogen Idec Inc., of Weston, Mass., received conditional approval from the European Commission for Fampyra (fampridine) to improve walking in people with multiple sclerosis
The European Commission approved Benlysta (belimumab) by GlaxoSmithKline plc, of London, and Human Genome Sciences Inc., of Rockville, Md., for lupus erythematosus
Inc., of Whitehouse Station, N.J., reported that the European Commission has approved Victrelis (boceprevir) for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adults with untreated compensated liver disease and those who have failed previous therapy
Amgen Inc., of Thousand Oaks, Calif., said the European Commission approved Xgeva (denosumab) for the prevention of skeletal-related events (SRE) in adults with bone metastases from solid tumors
The European Commission approved Yervoy (iplimumab) by Bristol-Myers Squibb Co., of New York, for melanoma...The European Commission approved Benlysta (belimumab) by GlaxoSmithKline plc, of London, and Human Genome Sciences Inc., of Rockville, Md., for lupus erythematosus
Roche AG, of Basel, Switzerland, said the European Commission (EC) extended the existing Avastin (bevacizumab) metastatic breast cancer label to include combination with Xeloda (capecitabine
Roche AG, of Basel, Switzerland, said the European Commission (EC) extended the existing Avastin (bevacizumab) metastatic breast cancer label to include combination with Xeloda (capecitabine
plc, of Dublin, Ireland, and Biogen Idec Inc., of Weston, Mass., said the European Commission approved a label change for multiple sclerosis drug Tysabri (natalizumab), adding anti-JC virus antibody status as a factor to aid in stratifying patients at risk for developing progressive multifocal leukoencephalopathy
plc, of Dublin, Ireland, said the European Commission approved a label change for multiple sclerosis drug Tysabri (natalizumab), adding anti-JC virus antibody status as a factor to aid in stratifying patients at risk for developing progressive multifocal leukoencephalopathy
Amylin Pharmaceuticals Inc., of San Diego, Alkermes Inc., of Waltham, Mass., and Eli Lilly and Co., of Indianapolis, said the European Commission approved Bydureon (exenatide), a once-weekly version of GLP-1 receptor agonist Byetta, for Type II diabetes in adults in combination with metformin, a sulfonylurea, a thiazolidinedione, metformin plus a sulfonylurea or metformin plus a thiazolidinedione
The project will be funded primarily by the European Commission Seventh Framework Program